Companies / BOC Sciences / Dacetuzumab
BOC Sciences

Dacetuzumab | BOC Sciences

Dacetuzumab is an anti-CD40 monoclonal antibody that has been developed for the treatment of relapsed diffuse large B-cell lymphoma (DLBCL).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.